In vivo assessment of the combination of the JAK1 selective inhibitor itacitinib with first- and second-generation EGFR inhibitors in models of non-small cell lung cancer

被引：2

作者：

Stubbs, Matthew C. ^{[1
]}

Wen, Xiaoming ^{[1
]}

Xue, Chu-Biao ^{[1
]}

Huang, Taisheng ^{[1
]}

Yao, Wenqing ^{[1
]}

Metcalf, Brian ^{[1
]}

Huber, Reid ^{[1
]}

Scherle, Peggy ^{[1
]}

Ruggeri, Bruce ^{[1
]}

机构：

[1] Incyte Corp, Wilmington, DE USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-2938

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2938

引用

页数：2

共 50 条

[21] Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer
Nagano, T.
Tachihara, M.
Nishimura, Y.
DRUGS OF TODAY, 2019, 55 (04) : 231 - 236
[22] Molecular Spectrum of Patients with JAK1 Mutations in East Asian Non-Small Cell Lung Cancer
Yu, X.
Xu, C.
Wang, W.
Zhang, Q.
Zhuang, W.
Zhu, Y.
Huang, Y.
Chen, G.
Fang, M.
Lv, T.
Song, Y.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S953 - S954
[23] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Fong, Thomas
Morgensztern, Daniel
Govindan, Ramaswamy
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
[24] Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer
Rothschild, Sacha I.
TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 379 - 381
[25] Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer
Li, Qianping
Ma, Weijie
Li, Tianhong
JOURNAL OF THORACIC DISEASE, 2018, 10 : S3186 - S3191
[26] Second- and third-generation ALK inhibitors for non-small cell lung cancer
Jingjing Wu
John Savooji
Delong Liu
Journal of Hematology & Oncology, 9
[27] Second- and third-generation ALK inhibitors for non-small cell lung cancer
Wu, Jingjing
Savooji, John
Liu, Delong
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
[28] SECOND-GENERATION SEQUENCING OF NON-SMALL CELL LUNG CANCER: IDENTIFICATION OF MUTATIONS ASSOCIATED WITH PROGRESSIVE DISEASE
Hyde, Russell
Raji, Olaide Y.
Olohan, Lisa
Vasieva, Olga
Ashelford, Kevin
Brass, Andy
Page, Richard D.
Hall, Neil
Field, John K.
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S589 - S589
[29] Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer
Huang, Tinglei
Chen, Biying
Wang, Feng
Cai, Weiyang
Wang, Xinxin
Huang, Bo
Liu, Feng
Jiang, Bin
Zhang, Yanjie
CANCER LETTERS, 2021, 523 : 182 - 194
[30] Primary and secondary resistance mechanisms in first, second and third generation tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer patients.
Suryavanshi, Moushumi
Mattoo, Sakshi
Sharma, Sanjeev Kumar
Mehta, Anurag
Batra, Ullas
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →